CD274 and neoplasm: Checkpoint blockade therapy (which targets the interaction between PD-1 and PD-L1) promotes T cell-mediated tumor immune surveillance, and has achieved remarkable clinical efficacy in various cancers, including lung cancer, melanoma, bladder cancer, renal cell cancer, and colorectal cancer (198).